Matching articles for "Thalitone"
In Brief: Low-Dose Chlorthalidone (HemiClor) for Hypertension
The Medical Letter on Drugs and Therapeutics • July 21, 2025; (Issue 1733)
The FDA has approved a 12.5-mg tablet formulation
of the thiazide-like diuretic chlorthalidone (HemiClor –
Ingenus) for treatment of hypertension. Chlorthalidone
has been available for years in 15-, 25-,...
The FDA has approved a 12.5-mg tablet formulation
of the thiazide-like diuretic chlorthalidone (HemiClor –
Ingenus) for treatment of hypertension. Chlorthalidone
has been available for years in 15-, 25-, and 50-mg
tablets (Thalitone, and generics) and in fixed-dose
combinations with azilsartan medoxomil (Edarbyclor)
and atenolol (Tenoretic, and generics).
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • May 27, 2024; (Issue 1703)
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines for treatment of
hypertension were last published in 2018. Treatment
of hypertensive urgencies and emergencies is not
discussed...
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines for treatment of
hypertension were last published in 2018. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
Edarbyclor: An ARB/Chlorthalidone Combination for Hypertension
The Medical Letter on Drugs and Therapeutics • March 5, 2012; (Issue 1385)
The FDA has approved a fixed-dose combination of
the angiotensin receptor blocker (ARB) azilsartan and
the thiazide-like diuretic chlorthalidone as Edarbyclor
(Takeda) for treatment of...
The FDA has approved a fixed-dose combination of
the angiotensin receptor blocker (ARB) azilsartan and
the thiazide-like diuretic chlorthalidone as Edarbyclor
(Takeda) for treatment of hypertension
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • January 1, 2012; (Issue 113)
Drugs available in the US for treatment of chronic
hypertension, with their dosages and adverse effects,
are listed in the tables that begin on page 2.
Combination products are listed on page 8. Drugs...
Drugs available in the US for treatment of chronic
hypertension, with their dosages and adverse effects,
are listed in the tables that begin on page 2.
Combination products are listed on page 8. Drugs for
treatment of hypertensive emergencies are not discussed
here. They were reviewed previously.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • January 1, 2009; (Issue 77)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines (volume 1, page 19, December 2002) and in The Medical Letter (volume 50, page 73, September 22, 2008).
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • June 1, 2005; (Issue 34)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs for treatment of hypertensive emergencies are not discussed here.
Microx
The Medical Letter on Drugs and Therapeutics • June 17, 1988; (Issue 768)
Microx (Pennwalt), a new low-dosage formulation of the thiazide-type diuretic metolazone (Zaroxolyn; Diulo), was recently marketed in the USA. The manufacturer claims that the low dose of controls...
Microx (Pennwalt), a new low-dosage formulation of the thiazide-type diuretic metolazone (Zaroxolyn; Diulo), was recently marketed in the USA. The manufacturer claims that the low dose of controls hypertension with less potassium loss, making it safer than other diuretics and as effective as combination drugs, such as Dyazide, that include both a thiazide and a potassium-sparing diuretic. Medical Letter consultants generally do not recommend Dyazide or other fixed-dose combinations for treatment of hypertension.